Is Venetoclax Retreatment Effective in Relapsed CLL?
A review of clinical evidence indicates that venetoclax re-exposure is associated with high response rates in patients with relapsed chronic lymphocytic leukemia (CLL). The overall response rates ranged from 72% to 100%, while median progression-free survival varied between 23 to 58 months. However, the evidence remains preliminary, with heterogeneous patient populations and varying treatment regimens complicating direct comparisons.
- ▪Venetoclax re-exposure was associated with high overall response rates and promising progression-free survival in selected patients with relapsed CLL.
- ▪The overall response rates ranged from 72% to 100%, with undetectable minimal residual disease rates in peripheral blood ranging from 32% to 92%.
- ▪Median progression-free survival after retreatment varied across cohorts from approximately 23 to 58 months.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:Venetoclax re-exposure — usually in combination with an anti-CD20 antibody or a Bruton tyrosine kinase (BTK) inhibitor — was associated with high overall response rates and promising progression-free survival (PFS) in selected patients with relapsed chronic lymphocytic leukemia (CLL), according to a review of clinical evidence. Across several studies, the overall response rates ranged from 72% to 100%, with rates of undetectable minimal residual disease in peripheral blood ranging from 32% to 92%. Median PFS ranged from approximately 23 to 58 months.METHODOLOGY:Fixed-duration venetoclax combinations are widely used in both frontline and relapsed or refractory CLL.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
